Nicholas Hoffman & Company’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.22M | Sell |
10,203
-32
| -0.3% | -$7.1K | 0.05% | 78 |
|
|
2025
Q4 | $2.34M | Sell |
10,235
-18
| -0.2% | -$4.1K | 0.05% | 74 |
|
|
2025
Q3 | $2.37M | Buy |
10,253
+104
| +1% | +$21.2K | 0.06% | 74 |
|
|
2025
Q2 | $1.88M | Buy |
10,149
+2,918
| +40% | +$542K | 0.05% | 82 |
|
|
2025
Q1 | $1.51M | Sell |
7,231
-650
| -8% | -$126K | 0.06% | 90 |
|
|
2024
Q4 | $1.4M | Buy |
7,881
+250
| +3% | +$46K | 0.06% | 92 |
|
|
2024
Q3 | $1.51M | Sell |
7,631
-34
| -0.4% | -$6.35K | 0.06% | 90 |
|
|
2024
Q2 | $1.31M | Buy |
7,665
+4
| +0.1% | +$663 | 0.06% | 97 |
|
|
2024
Q1 | $1.4M | Buy |
7,661
+3
| +0% | +$517 | 0.07% | 91 |
|
|
2023
Q4 | $1.19M | Buy |
7,658
+317
| +4% | +$46.2K | 0.07% | 104 |
|
|
2023
Q3 | $1.09M | Sell |
7,341
-197
| -3% | -$28.9K | 0.08% | 100 |
|
|
2023
Q2 | $1.02M | Sell |
7,538
-342
| -4% | -$50.2K | 0.04% | 113 |
|
|
2023
Q1 | $1.26M | Buy |
7,880
+3
| +0% | +$459 | 0.11% | 92 |
|
|
2022
Q4 | $1.27M | Sell |
7,877
-3
| -0% | -$460 | 0.14% | 96 |
|
|
2022
Q3 | $1.06M | Buy |
7,880
+89
| +1% | +$12.8K | 0.05% | 101 |
|
|
2022
Q2 | $1.19M | Sell |
7,791
-75
| -1% | -$11.5K | 0.06% | 92 |
|
|
2022
Q1 | $1.27M | Sell |
7,866
-219
| -3% | -$31.8K | 0.05% | 88 |
|
|
2021
Q4 | $1.09M | Sell |
8,085
-47
| -0.6% | -$5.55K | 0.04% | 100 |
|
|
2021
Q3 | $877K | Buy |
8,132
+1,006
| +14% | +$115K | 0.15% | 118 |
|
|
2021
Q2 | $803K | Buy |
7,126
+5
| +0.1% | +$563 | 0.14% | 122 |
|
|
2021
Q1 | $771K | Buy |
7,121
+359
| +5% | +$38.4K | 0.16% | 120 |
|
|
2020
Q4 | $725K | Buy |
6,762
+752
| +13% | +$72.3K | 0.17% | 109 |
|
|
2020
Q3 | $526K | Buy |
6,010
+553
| +10% | +$52.1K | 0.14% | 121 |
|
|
2020
Q2 | $536K | Sell |
5,457
-3,795
| -41% | -$334K | 0.15% | 121 |
|
|
2020
Q1 | $705K | Buy |
9,252
+1,058
| +13% | +$90.1K | 0.24% | 88 |
|
|
2019
Q4 | $726K | Hold |
8,194
| – | – | 0.2% | 107 |
|
|
2019
Q3 | $620K | Buy |
8,194
+1
| +0% | +$69 | 0.19% | 116 |
|
|
2019
Q2 | $596K | Buy |
8,193
+1
| +0% | +$79 | 0.19% | 114 |
|
|
2019
Q1 | $660K | Buy |
8,192
+1,260
| +18% | +$103K | 0.21% | 105 |
|
|
2018
Q4 | $639K | Buy |
6,932
+2,388
| +53% | +$210K | 0.22% | 95 |
|
|
2018
Q3 | $430K | Buy |
4,544
+933
| +26% | +$88.5K | 0.14% | 119 |
|
|
2018
Q2 | $335K | Buy |
3,611
+728
| +25% | +$71.1K | 0.12% | 126 |
|
|
2018
Q1 | $273K | Buy |
2,883
+57
| +2% | +$6.26K | 0.11% | 141 |
|
|
2017
Q4 | $273K | Buy |
2,826
+106
| +4% | +$9.99K | 0.11% | 136 |
|
|
2017
Q3 | $242K | Buy |
+2,720
| New | +$207K | 0.1% | 140 |
|
Other funds holding ABBV
VCM
VPM
Nicholas Hoffman & Company's ABBV Position: Q1 2026 in Review
Nicholas Hoffman & Company reduced its AbbVie (ABBV) stake by 0.31% in Q1 2026, selling an estimated $7.1K and leaving 10,203 shares worth $2.22M. The position accounts for 0.05% of the portfolio, ranked #78.
Nicholas Hoffman & Company first reported a position in ABBV in Q3 2017 and has held it in 35 quarters since. The position peaked at $2.37M in Q3 2025. 4,081 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Nicholas Hoffman & Company held 10,203 shares of AbbVie worth $2.22M as of Q1 2026.
- Nicholas Hoffman & Company sold 32 AbbVie shares in Q1 2026, an estimated $7.1K.
- AbbVie made up 0.05% of Nicholas Hoffman & Company's portfolio in Q1 2026, its #78 holding.
- Nicholas Hoffman & Company first reported a position in AbbVie in Q3 2017 and has held it in 35 quarters since.
- Nicholas Hoffman & Company's AbbVie position peaked at $2.37M in Q3 2025.
- 4,081 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Nicholas Hoffman & Company's 13F filing for Q1 2026, filed 29 Apr 2026.